01 XTALPI'S PEPITIDE PLATFORM
PepiX™
The AI Path to Peptide Medicine
PepiX™ is XtalPi’s AI-powered platform for peptide drug discovery, integrating AI-driven de novo design and druggability prediction with automated synthesis, high-throughput experimental screening, and proprietary non-canonical amino acid (NCAA) technologies. By connecting dry-lab AI design with iterative wet-lab validation in a closed-loop workflow, PepiX™ accelerates the discovery and optimization of peptide candidates with high affinity, improved stability, and stronger potential for clinical translation.
02
Technology Engine
AI + Lab Dual Engines Power Three Innovation Areas
Driven by its dual engines, PepiX.AI and PepiX.LAB, PepiX™ integrates dry-lab design and wet-lab validation into a closed-loop peptide discovery workflow.
Integrated R&D Model
PepiX™ is powered by two complementary technology engines: PepiX.AI, which enables AI-driven de novo peptide design and druggability prediction, and PepiX.LAB, which delivers high-throughput wet-lab screening guided by AIDD analysis.
Proprietary NCAA incorporation further expands the accessible chemical space and enhances peptide druggability, while automated synthesis accelerates iterative design–make–test cycles across the integrated dry–wet lab workflow.
PepiX™ is powered by two complementary technology engines: PepiX.AI, which enables AI-driven de novo peptide design and druggability prediction, and PepiX.LAB, which delivers high-throughput wet-lab screening guided by AIDD analysis.
Proprietary NCAA incorporation further expands the accessible chemical space and enhances peptide druggability, while automated synthesis accelerates iterative design–make–test cycles across the integrated dry–wet lab workflow.
Strategic Focus
PepiX™ supports the discovery and development of complex peptide therapeutics, with a strategic focus on brain & ocular delivery, oral cyclic peptides, and peptide conjugates, accelerating the discovery and translation of high-quality peptide candidates.
PepiX™ supports the discovery and development of complex peptide therapeutics, with a strategic focus on brain & ocular delivery, oral cyclic peptides, and peptide conjugates, accelerating the discovery and translation of high-quality peptide candidates.
Peptide Conjugates
Selectivity / Stability / High Affinity (pM-level)
Oral Cyclic Peptides
Stability / Affinity / Bioavailability
Brain / Ocular Delivery
Selectivity
03
Pipeline Progress
Peptide Pipeline Across Diverse Targets and Indications
To date, PepiX™ has established a growing portfolio of peptide pipelines focused on brain & ocular delivery, oral cyclic peptides, and peptide conjugates, spanning a range of disease-relevant targets and indications. These pipelines continue to demonstrate the platform’s scalability in peptide design and multi-parameter optimization, while generating differentiated peptide candidates with the potential to advance into high-value therapeutic assets.
Partnering to accelerate peptide R&D
Powered by PepiX™, XtalPi’s AI-driven peptide drug discovery platform, we have established an iterative, multi-objective optimization framework to continuously discover and advance differentiated peptide assets with high affinity, enhanced stability, and strong druggability potential.
We offer two primary collaboration models: asset licensing and platform-based collaboration. Through these flexible partnership models, we work with pharmaceutical and biotechnology companies worldwide to unlock the therapeutic potential of peptide drugs and accelerate the development of breakthrough therapies for patients globally.
We offer two primary collaboration models: asset licensing and platform-based collaboration. Through these flexible partnership models, we work with pharmaceutical and biotechnology companies worldwide to unlock the therapeutic potential of peptide drugs and accelerate the development of breakthrough therapies for patients globally.